VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On January 7, 2021, members of management of VYNE Therapeutics Inc. (the "Company") will begin using the investor presentation attached as Exhibit 99.1 to this report in connection with investor meetings and industry conferences.

The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith.

     Exhibit No.                            Description
       99.1        Investor Presentation, January 2021.

     104         Cover Page Interactive Date File (embedded within the Inline XBRL
                 document).

© Edgar Online, source Glimpses